Disease · MONDO_0002334
hematopoietic and lymphoid system neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. hematopoietic and lymphoid system neoplasm. Diseases, record MONDO_0002334. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0002334
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
blood neoplasm (disease), blood tumor, blood tumour, haematological tumours, haematopoietic and lymphoid system tumour, haematopoietic system neoplasm, haematopoietic system tumour, haematopoietic tumours, hematopoietic and lymphoid system tumor, hematopoietic system neoplasm, hematopoietic system tumor, neoplasm of blood, neoplasm of haematopoietic system, neoplasm of hematopoietic system, tumor of blood, tumor of hematopoietic system, tumour of blood, tumour of haematopoietic system
- Open Targets
Drugs38
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| FLUDARABINE | CHEMBL1568 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| AUTOLOGOUS CORD BLOOD | CHEMBL4594461 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| DILANUBICEL | CHEMBL4297239 | Cell | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| FLUDARABINE PHOSPHATE | CHEMBL1096882 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| MYCOPHENOLATE MOFETIL | CHEMBL1456 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PALIFERMIN | CHEMBL1201821 | Protein | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| SODIUM BICARBONATE | CHEMBL1353 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| TACROLIMUS ANHYDROUS | CHEMBL269732 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | CHEMBL2108981 | Phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 38
See all 38 drugsTargets40
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| SYK | Tyrosine-protein kinase SYK | 3 | Tyrosine-protein kinase SYK inhibitor | Unknown | https://conductscience.org/library/genes/6850 | Drugs and targets |
| JAK2 | Janus Kinase (JAK) | 2 | Janus Kinase (JAK) inhibitor; Tyrosine-protein kinase JAK2 inhibitor | Unknown | https://conductscience.org/library/genes/3717 | Drugs and targets |
| BTK | Tyrosine-protein kinase BTK | 1 | Tyrosine-protein kinase BTK inhibitor | Unknown | https://conductscience.org/library/genes/695 | Drugs and targets |
| CD19 | B-lymphocyte antigen CD19 | 1 | B-lymphocyte antigen CD19 binding agent | Unknown | https://conductscience.org/library/genes/930 | Drugs and targets |
| CD3D | T cell surface glycoprotein CD3 | 1 | T cell surface glycoprotein CD3 binding agent | Unknown | https://conductscience.org/library/genes/915 | Drugs and targets |
| CD3E | T cell surface glycoprotein CD3 | 1 | T cell surface glycoprotein CD3 binding agent | Unknown | https://conductscience.org/library/genes/916 | Drugs and targets |
| CD3G | T cell surface glycoprotein CD3 | 1 | T cell surface glycoprotein CD3 binding agent | Unknown | https://conductscience.org/library/genes/917 | Drugs and targets |
| CDK1 | Cyclin-dependent kinase 1 | 1 | Cyclin-dependent kinase 1 inhibitor | Unknown | https://conductscience.org/library/genes/983 | Drugs and targets |
| CDK2 | Cyclin-dependent kinase 2 | 1 | Cyclin-dependent kinase 2 inhibitor | Unknown | https://conductscience.org/library/genes/1017 | Drugs and targets |
| CDK7 | Cyclin-dependent kinase 7 | 1 | Cyclin-dependent kinase 7 inhibitor | Unknown | https://conductscience.org/library/genes/1022 | Drugs and targets |
1 to 10 of 40
See all 40 targetsTrials11
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | 57 | 2017-07-11 | Leukemia, Myeloid, Chronic, Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Lymphocytic, Acute, Leukemia, Lymphocytic, Chronic, AML | CYCLOPHOSPHAMIDE, FLUDARABINE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | Phase 2 | 31 | 2024-04-02 | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Aplastic Anemia, B-Cell Non-Hodgkin Lymphoma, CD40 Ligand Deficiency, Chronic Granulomatous Disease, Chronic Leukemia in Remission, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Congenital Amegakaryocytic Thrombocytopenia, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Glanzmann Thrombasthenia, Immunodeficiency Syndrome, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Paroxysmal Nocturnal Hemoglobinuria, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndrome, Severe Aplastic Anemia, Shwachman-Diamond Syndrome, Sickle Cell Disease, T-Cell Non-Hodgkin Lymphoma, Thalassemia, Waldenstrom Macroglobulinemia, Wiskott-Aldrich Syndrome | CYCLOPHOSPHAMIDE, FLUDARABINE PHOSPHATE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02806791 | Efficacy of Biosimilar Filgrastim on the Mobilization of Hematopoietic Stem Cell CD34+ (Cluster of Differentiation 34) and on the Kinetic Engraftment | 300 | Blood Diseases | FILGRASTIM | Open Targets' reading of its record | ClinicalTrials.gov | ||
| NCT04098393 | Giving Chemotherapy for a Shortened Amount of Time Before a Stem Cell Transplantation | Phase 1 | 39 | Hematologic Malignancies | BUSULFAN, FLUDARABINE, MELPHALAN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03399773 | Infusion of Expanded Cord Blood Cells in Addition to Single Cord Blood Transplant in Treating Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplastic Syndromes | Phase 2 | 31 | Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts | DILANUBICEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03712878 | 2-Step Approach to Stem Cell Transplant in Treating Participants With Hematological Malignancies | Phase 2 | 10 | Hematopoietic and Lymphoid Cell Neoplasm | MYCOPHENOLATE MOFETIL, TACROLIMUS ANHYDROUS | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT00570999 | Palifermin After Haploidentical PBSCT | Phase 2 | 0 | Non-Hodgkin's Lymphoma or Hodgkin's Disease, Acute Leukaemia, Myelodysplastic Syndrome, Chronic Myeloid Leukemia, Osteomyelofibrosis | PALIFERMIN | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03348826 | Study of Sodium Bicarbonate in Restoring Blocked Catheters | Phase 2 | 0 | Cancer, Central Venous Catheterization | SODIUM BICARBONATE | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03807063 | Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant | Phase 1 | 0 | Acute Bilineal Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloproliferative Neoplasm, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome | RIMIDUCID, RIVOGENLECLEUCEL | Open Targets' reading of its record | ClinicalTrials.gov | |
| NCT03206931 | Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion | Solid Tumors Harboring NTRK Fusion | SELITRECTINIB | Open Targets' reading of its record | ClinicalTrials.gov |
1 to 10 of 11
See all 11 trialsComparisons in its trials7
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients With Acute Graft-Versus-Host Disease | 10 of 15 | 10 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive Without Disease | 2 of 15 | 10 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients With Bone Marrow Aplasia | 0 of 15 | 1 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Participants With Complete Remission | 7 of 15 | 22 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: Number of Patients Alive | 3 of 15 | 20 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: deaths from any cause | 12 of 15 | 22 of 42 | 57 | NCT00167180 | Trial comparisons |
| DLI Cell Dose of 1.0 x 10^8 CD3+ T-cells/kg vs DLI Cell Dose of 0.5 x 10^8 CD3+ T-cells/kg: serious adverse events | 8 of 15 | 3 of 42 | 57 | NCT00167180 | Trial comparisons |
Papers from its trials1
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it |
|---|---|---|
| 17579184 | DERIVED | 1 |
Source PubMed
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002334
GET https://conductscience.org/api/diseases/v1/MONDO_0002334/drugs?page=2